Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mark W. Pasmantier"'
Autor:
Mildred Chen, James P. Smith, Juan P. Wisnivesky, David F. Yankelevitz, Dorothy I. McCauley, Javier J. Zulueta, Ali Farooqi, Daniel M. Libby, Mark W. Pasmantier, Claudia I. Henschke, Rowena Yip
Publikováno v:
Chest. 141:1216-1223
Our objective was to assess the usefulness of emphysema scores in predicting death from COPD and lung cancer.Emphysema was assessed with low-dose CT scans performed on 9,047 men and women for whom age and smoking history were documented. Each scan wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1886a72db9cf73f9dda8f7a0ec84e1
https://doi.org/10.1378/chest.11-0101
https://doi.org/10.1378/chest.11-0101
Autor:
David F. Yankelevitz, Anthony P. Reeves, Daniel M. Libby, Rowena Yip, Olli S. Miettinen, Mark W. Pasmantier, Claudia I. Henschke, Ali Farooqi, Dongming Xu, James P. Smith
Publikováno v:
Radiology. 263:578-583
Purpose To empirically address the distribution of the volume doubling time (VDT) of lung cancers diagnosed in repeat annual rounds of computed tomographic (CT) screening in the International Early Lung Cancer Action Program (I-ELCAP), first and fore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e33fe9c2be9d10f19fec2487b175cfa
https://doi.org/10.1148/radiol.12102489
https://doi.org/10.1148/radiol.12102489
Autor:
Bhupesh Parashar, A. Gabriella Wernicke, K. S. Clifford Chao, Mark W. Pasmantier, Rajeev Mehta, Roger S. Kerestez, Albert Sabbas, Alison Edwards, Dattatreyudu Nori
Publikováno v:
American Journal of Clinical Oncology. 34:160-164
INTRODUCTION The reported rate of developing radiation pneumonitis (RP) in patients receiving definitive radiation therapy (RT) for lung cancer is 5% to 36%. However, this incidence is probably underreported because of the nonspecific symptoms of RP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc61d7da4d7dcfa287a0e9f32a483ae3
https://doi.org/10.1097/coc.0b013e3181d6b40f
https://doi.org/10.1097/coc.0b013e3181d6b40f
Autor:
Mark W. Pasmantier, Andrew R. Branagan, Henry Sonneborn, Bryan Ciccarelli, Jacob D. Soumerai, Zachary R. Hunter, David R. Lovett, Leukothea Ioakimidis, Kenneth C. Anderson, John M. Howard, Robert B. Cooper, Paul Musto, Hans Boedeker, Steven P. Treon, Alan Rauch, Cynthia Chua, Lawrence Garbo, Luis Chu, Maria Moore, John M. Hill, Frederick M. Briccetti, Stephen H. Nantel, Evdoxia Hatjiharissi, Harvey Zimbler, Christopher J. Patterson
Publikováno v:
Blood. 112:4452-4457
Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9473f8afb3aa3b60dccee974d0688c
https://doi.org/10.1182/blood-2008-04-150854
https://doi.org/10.1182/blood-2008-04-150854
Autor:
Daniel M. Libby, David F. Yankelevitz, Olli S. Miettinen, James P. Smith, Mark W. Pasmantier, Claudia I. Henschke
Publikováno v:
New England Journal of Medicine. 355:1763-1771
BACKGROUND The outcome among patients with clinical stage I cancer that is detected on annual screening using spiral computed tomography (CT) is unknown. METHODS In a large collaborative study, we screened 31,567 asymptomatic persons at risk for lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a3ea11a5f917f1160ab760c16d75cd
https://doi.org/10.1056/nejmoa060476
https://doi.org/10.1056/nejmoa060476
Autor:
Ning Wu, Ali Farooqi, David F. Yankelevitz, James P. Smith, Dorothy I. McCauley, Daniel M. Libby, In-Jae Lee, Mark W. Pasmantier, Claudia I. Henschke
Publikováno v:
Chest. 129:1039-1042
Background Although CT screening for lung cancer results in a diagnosis of stage I > 80% of the time, benign noncalcified nodules are also found. We recognized that some nodules appeared to represent infectious bronchopneumonia or other inflammatory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6eef16ab69b6fa356b35b676348c620
https://doi.org/10.1378/chest.129.4.1039
https://doi.org/10.1378/chest.129.4.1039
Autor:
David P. Naidich, Daniel M. Libby, James P. Smith, David F. Yankelevitz, Olli S. Miettinen, Ali Farooqi, Georgeann McGuinness, Madeline Vasquez, Dorothy I. McCauley, Mark W. Pasmantier, Claudia I. Henschke
Publikováno v:
Clinical Imaging. 28:317-321
Purpose The purpose of this study was to characterize the diagnostic performance of a regimen of CT screening for lung cancer. Methods Using a common protocol/regimen of screening, 2968 asymptomatic persons at high risk for lung cancer were enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::421d4e752f46955d0068e1f2e80e0b53
https://doi.org/10.1016/j.clinimag.2004.05.001
https://doi.org/10.1016/j.clinimag.2004.05.001
Autor:
Nasser K. Altorki, David F. Yankelevitz, Daniel M. Libby, James P. Smith, Mark W. Pasmantier, Claudia I. Henschke
Publikováno v:
Chest. 125:1522-1529
Objectives To review the Early Lung Cancer Action Project experience and the medical literature from 1993 to 2003 on detection of the small, noncalcified pulmonary nodule by CT in order to formulate a management algorithm for these nodules. Design Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38e5dba2bc6cda14c60d88262cb6726
https://doi.org/10.1378/chest.125.4.1522
https://doi.org/10.1378/chest.125.4.1522
Autor:
David F. Yankelevitz, James P. Smith, David P. Naidich, Mark W. Pasmantier, Daniel M. Libby, Claudia I. Henschke, Olli S. Miettinen, Dorothy I. McCauley, Georgeann McGuinness
Publikováno v:
Radiology. 231:164-168
To assess the frequency with which a particular, possibly optimal work-up of noncalcified nodules less than 5.0 mm in diameter identified on initial computed tomographic (CT) images at baseline screening leads to a diagnosis of malignancy prior to fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ba377853942bd59ea98128a850368d
https://doi.org/10.1148/radiol.2311030634
https://doi.org/10.1148/radiol.2311030634
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 126(5):1603-1608
Objective Paclitaxel has one of the highest response rates when used as a single agent in patients with esophageal cancer. The combination of paclitaxel and carboplatin has been shown to be a well-tolerated and safe regimen in non–small cell lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5af3ab252b93c343dd7aad972d95264